ADHD drug developer Cingulate sets terms for $50 million IPO - (Renaissance Capital via NewsPoints Desk)

  • Cingulate announced on Monday that it plans to raise $50 million in its initla public offering by offering 4.5 million shares at a price range of $10 to $12, as reported Renaissance Capital.

  • At the midpoint of this range, the company would command a market value of $225 million.

  • Cingulate is initially focusing on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), and initially targeting the ADHD stimulant-based treatment market. 

To read more NewsPoints articles, click here.

Reference Articles